GB2397018B - Combination therapy for treating disease - Google Patents

Combination therapy for treating disease

Info

Publication number: GB2397018B
Authority: GB; United Kingdom
Prior art keywords: combination therapy; treating disease; disease; treating; therapy
Prior art date: 2001-10-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

GB0409191A

Other versions

GB2397018A (en

GB0409191D0 (en

Inventor

Birgit C Schultes

Christopher F Nicodemus

Antoine Noujaim

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Altarex Medical Corp

Original Assignee

Altarex Medical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-26

Filing date

2002-10-28

Publication date

2006-05-31

2002-10-28 Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp

2004-05-26 Publication of GB0409191D0 publication Critical patent/GB0409191D0/en

2004-07-14 Publication of GB2397018A publication Critical patent/GB2397018A/en

2006-05-31 Application granted granted Critical

2006-05-31 Publication of GB2397018B publication Critical patent/GB2397018B/en

2022-10-28 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Pregnancy & Childbirth (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gynecology & Obstetrics (AREA)
Genetics & Genomics (AREA)
Reproductive Health (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

GB0409191A 2001-10-26 2002-10-28 Combination therapy for treating disease Expired - Fee Related GB2397018B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33924001P	2001-10-26	2001-10-26
PCT/IB2002/005794 WO2003034977A2 (en)	2001-10-26	2002-10-28	Combination therapy for treating disease

Publications (3)

Publication Number	Publication Date
GB0409191D0 GB0409191D0 (en)	2004-05-26
GB2397018A GB2397018A (en)	2004-07-14
GB2397018B true GB2397018B (en)	2006-05-31

Family

ID=23328122

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GB0409191A Expired - Fee Related GB2397018B (en)	2001-10-26	2002-10-28	Combination therapy for treating disease

Country Status (9)

Country	Link
AT (1)	AT500649A1 (en)
AU (1)	AU2002358246B2 (en)
CA (1)	CA2464947C (en)
CH (1)	CH696871A5 (en)
DE (1)	DE10297379T5 (en)
ES (1)	ES2304264A1 (en)
GB (1)	GB2397018B (en)
NO (1)	NO20042166L (en)
WO (1)	WO2003034977A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8038994B2 (en)	1996-05-15	2011-10-18	Quest Pharmatech Inc.	Combination therapy for treating disease
WO2008091643A2 (en) *	2007-01-23	2008-07-31	Altarex Medical Corp.	In vitro culture system to evaluate synergy in targeting immune suppressive pathways concurrent to immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001000245A2 (en) *	1999-06-25	2001-01-04	Genentech, Inc.	HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2001007082A1 (en) *	1999-07-23	2001-02-01	Glaxo Group Limited	Combination of an anti-ep-cam antibody with a chemotherapeutic agent
WO2001059452A2 (en) *	2000-02-08	2001-08-16	Altarex Corp.	Method for diagnosing efficacy of xenotypic antibody therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2163868C (en) *	1993-05-27	2008-01-08	Uwe Wagner	Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them
EP1297846A1 (en) *	1996-05-15	2003-04-02	Altarex Corporation	Method and composition for reconforming multi-epitopic antigens to initiate an immune response
ES2239032T3 (en) *	1999-08-18	2005-09-16	Altarex Medical Corp.	THERAPEUTIC ANTIBODY AGAINST THE MUC-1 ANTIGEN AND METHODS FOR USE.
DE60042693D1 (en) *	1999-08-27	2009-09-17	Genentech Inc	DOSAGE FOR TREATMENT WITH ANTI ERBB2 ANTIBODIES
ES2293751B1 (en) *	2001-03-21	2009-03-16	Altarex Medical Corp.	THERAPEUTIC COMPOSITIONS THAT ALTER THE IMMUNE RESPONSE (ALT-014PC).

2002
- 2002-10-28 ES ES200450028A patent/ES2304264A1/en active Pending
- 2002-10-28 CA CA2464947A patent/CA2464947C/en not_active Expired - Lifetime
- 2002-10-28 DE DE10297379T patent/DE10297379T5/en not_active Withdrawn
- 2002-10-28 AT AT0923902A patent/AT500649A1/en not_active Application Discontinuation
- 2002-10-28 WO PCT/IB2002/005794 patent/WO2003034977A2/en not_active Ceased
- 2002-10-28 AU AU2002358246A patent/AU2002358246B2/en not_active Ceased
- 2002-10-28 GB GB0409191A patent/GB2397018B/en not_active Expired - Fee Related
- 2002-10-28 CH CH00729/04A patent/CH696871A5/en not_active IP Right Cessation
2004
- 2004-05-25 NO NO20042166A patent/NO20042166L/en not_active Application Discontinuation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001000245A2 (en) *	1999-06-25	2001-01-04	Genentech, Inc.	HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2001007082A1 (en) *	1999-07-23	2001-02-01	Glaxo Group Limited	Combination of an anti-ep-cam antibody with a chemotherapeutic agent
WO2001059452A2 (en) *	2000-02-08	2001-08-16	Altarex Corp.	Method for diagnosing efficacy of xenotypic antibody therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Blood, Vol.92, 1998, Davis, T. A. et al., "Anti-idiotype antibodies...", pp.1184-1190 *
Crit. Rev. Oncol./Hematol., Vol.40, 2001, Schwartzberg, L. S., "Clinical experience with edrecolomab...", pp.17-24 *
Drugs, Vol.56, 1998, Adkins, J. C. et al., "Edrecolomab...", pp.619-626 *
Semin. Oncol., Vol.28, Feb 2001, Haller, D., "Update of clinical trials...", pp.25-30 *

Also Published As

Publication number	Publication date
CA2464947C (en)	2012-05-22
DE10297379T5 (en)	2004-10-14
AT500649A1 (en)	2006-02-15
CH696871A5 (en)	2008-01-15
GB2397018A (en)	2004-07-14
ES2304264A1 (en)	2008-10-01
WO2003034977A2 (en)	2003-05-01
WO2003034977A3 (en)	2004-05-27
NO20042166L (en)	2004-05-25
AU2002358246B2 (en)	2008-02-28
CA2464947A1 (en)	2003-05-01
GB0409191D0 (en)	2004-05-26

Publication	Publication Date	Title
IL251270A0 (en)	2017-06-29	Cancer treatment
IL159344A0 (en)	2004-06-01	Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160884A0 (en)	2004-08-31	Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
EP1463438A4 (en)	2008-01-23	Endomural therapy
GB0112343D0 (en)	2001-07-11	Well treatment
GB0123951D0 (en)	2001-11-28	Therapies for treating respiratory diseases
GB0126879D0 (en)	2002-01-02	Combination therapy
IL159887A0 (en)	2004-06-20	Combination therapy for the treatment of cancer
GB0108671D0 (en)	2001-05-30	Skin treatment
GB0001710D0 (en)	2000-03-15	Therapeutic treatment
IL155237A0 (en)	2003-11-23	Combination therapy for the treatment of estrogen-sensitive disease
GB0108485D0 (en)	2001-05-23	Combination therapy
GB0101933D0 (en)	2001-03-07	Therapy
AU2096002A (en)	2002-06-18	Therapeutic treatment
GB0029524D0 (en)	2001-01-17	Disease treatment
GB0130763D0 (en)	2002-02-06	Treatment methods
GB2397018B (en)	2006-05-31	Combination therapy for treating disease
HU0200253D0 (en)	2002-03-28	Combination therapy
GB0128628D0 (en)	2002-01-23	Disease treatment
GB0130191D0 (en)	2002-02-06	Therapeutic treatment
GB0130694D0 (en)	2002-02-06	Treatment
GB0118564D0 (en)	2001-09-19	Therapeutic treatment for tinnitus
GB0102559D0 (en)	2001-03-21	Treatment for angiogenesis-dependant condition
GB0119164D0 (en)	2001-09-26	Skin disease treatment
GB0127267D0 (en)	2002-01-02	Medical treatment

Legal Events

Date	Code	Title	Description
2016-01-13	732E	Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)	Free format text: REGISTERED BETWEEN 20151217 AND 20151223
2020-07-15	732E	Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)	Free format text: REGISTERED BETWEEN 20200618 AND 20200624
2020-11-25	732E	Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)	Free format text: REGISTERED BETWEEN 20201029 AND 20201104
2022-06-29	PCNP	Patent ceased through non-payment of renewal fee	Effective date: 20211028